Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.

Sabine AltrichterAna Maria Giménez-ArnauJonathan A BernsteinMartin MetzLila BahadoriMaria BergquistLaura BrooksCalvin N HoPriya JainPradeep B LukkaEva Rodriguez-SuárezClaire WaltonCatherine J Dattonull null

Published in: The British journal of dermatology (2024)

Although benralizumab resulted in near-complete depletion of blood eosinophils, there was no clinical benefit over placebo.

Keyphrases

placebo controlled
double blind
phase iii

phase ii
clinical trial
study protocol

phase ii study
open label

randomized controlled trial
squamous cell carcinoma